Overview

Inhaled Iloprost for Suspected COVID-19 Respiratory Failure

Status:
Recruiting
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.
Phase:
Phase 2
Details
Lead Sponsor:
Hamad Medical Corporation
Treatments:
Iloprost